CJC-1295 No DAC is a synthetic research peptide derived from growth hormone-releasing hormone (GHRH) and designed to interact with GHRH receptors involved in growth hormone signaling. Unlike DAC-modified formulations, CJC-1295 No DAC does not contain a Drug Affinity Complex, resulting in a shorter duration of activity that has made it useful in laboratory research involving transient peptide signaling and receptor response.

CJC-1295 No DAC research has explored its relationship with the growth hormone axis and biological mechanisms involved in growth hormone secretion. Researchers have investigated its interaction with GHRH receptors in experimental models examining pituitary signaling, pulsatile growth hormone release, and downstream pathways associated with insulin-like growth factor-1 (IGF-1).

Another area of CJC-1295 No DAC research involves cellular and metabolic signaling associated with the growth hormone axis. Laboratory studies have examined GHRH-related pathways in relation to cellular activity, protein metabolism, energy regulation, and neuroendocrine communication.

This 10mg formulation is supplied in a nasal research format for controlled laboratory investigation involving GHRH receptor activity, growth hormone signaling, IGF-1-related pathways, and associated biological mechanisms.